ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,522.30
      1.58%
      US Tech 100
      18,861.20
      0.10%
      Dow Jones
      40,842.79
      0.24%
      Brent Oil
      81.425
      -0.10%
      Bitcoin
      64,447.15
      -0.24%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. Johnson and Johnson (JNJ)

      7. Johnson and Johnson (JNJ) News

      JNJ

      Johnson and Johnson (JNJ)

      Johnson and Johnson
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:JNJ
      DateTimeSourceHeadlineSymbolCompany
      07/30/20249:06PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNYSE:JNJJohnson and Johnson
      07/30/20246:42PMPR Newswire (US)DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligibleNYSE:JNJJohnson and Johnson
      07/30/20246:00AMIH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNYSE:JNJJohnson and Johnson
      07/29/20244:00PMBusiness WireJohnson & Johnson to Participate in the 2024 Wells Fargo Healthcare ConferenceNYSE:JNJJohnson and Johnson
      07/26/20249:38AMBusiness WireCourts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step PlanNYSE:JNJJohnson and Johnson
      07/26/20249:05AMBusiness WireFINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation PlanNYSE:JNJJohnson and Johnson
      07/26/20246:07AMIH Market NewsAlphabet Unveils AlphaProof and AlphaGeometry 2; OpenAI Tests SearchGPT; Apple Loses Market Share in ChinaNYSE:JNJJohnson and Johnson
      07/25/20244:02PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:JNJJohnson and Johnson
      07/23/20244:00PMBusiness WireJohnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNYSE:JNJJohnson and Johnson
      07/22/202411:59AMBusiness WireLawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy PlanNYSE:JNJJohnson and Johnson
      07/22/20248:00AMPR Newswire (US)Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depressionNYSE:JNJJohnson and Johnson
      07/17/20248:14AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
      07/17/20246:30AMIH Market NewsTech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory DropNYSE:JNJJohnson and Johnson
      07/17/20246:28AMIH Market NewsSpirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings UpdatesNYSE:JNJJohnson and Johnson
      07/17/20246:25AMBusiness WireJohnson & Johnson Announces Quarterly Dividend for Third Quarter 2024NYSE:JNJJohnson and Johnson
      07/17/20246:20AMBusiness WireJohnson & Johnson reports Q2 2024 resultsNYSE:JNJJohnson and Johnson
      07/11/20247:30AMBusiness WireJohnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26NYSE:JNJJohnson and Johnson
      07/09/20245:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
      07/03/20248:00AMPR Newswire (Canada)Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNYSE:JNJJohnson and Johnson
      07/03/20248:00AMPR Newswire (Canada)Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules pNYSE:JNJJohnson and Johnson
      07/02/20247:30AMPR Newswire (US)CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 studyNYSE:JNJJohnson and Johnson
      06/28/202411:30AMPR Newswire (US)Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patientsNYSE:JNJJohnson and Johnson
      06/27/20246:46PMBusiness WireLawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in PurdueNYSE:JNJJohnson and Johnson
      06/21/20247:30AMBusiness WireJohnson & Johnson Completes Acquisition of Proteologix, Inc.NYSE:JNJJohnson and Johnson
      06/20/20244:30PMPR Newswire (US)Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's diseaseNYSE:JNJJohnson and Johnson
      06/20/20241:07PMBusiness WireMore than 60 Law Firms Oppose J&J Prepack Bankruptcy SchemeNYSE:JNJJohnson and Johnson
      06/20/20248:00AMPR Newswire (US)TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous inductionNYSE:JNJJohnson and Johnson
      06/20/20246:55AMIH Market NewsTrump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More NewsNYSE:JNJJohnson and Johnson
      06/17/20245:55PMBusiness WireBeasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc ProductsNYSE:JNJJohnson and Johnson
      06/17/20248:00AMPR Newswire (US)Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancerNYSE:JNJJohnson and Johnson
       Showing the most relevant articles for your search:NYSE:JNJ